Zealand Pharma A/S provided earnings guidance for the fiscal year 2022. For the period, the company expects net product revenue from the sales of its commercial products of DKK 235.0 million +/-10% compared to 2021 of DKK 184.0 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
611.5 DKK | -5.49% | +0.16% | +63.85% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+63.85% | 5.54B | |
+16.93% | 123B | |
+17.01% | 111B | |
-7.23% | 23.63B | |
+1.98% | 22.58B | |
-14.29% | 17.26B | |
-6.79% | 17.6B | |
-37.63% | 17.61B | |
+2.17% | 13.55B | |
+24.42% | 11.34B |
- Stock Market
- Equities
- ZEAL Stock
- News Zealand Pharma A/S
- Zealand Pharma A/S Provides Earnings Guidance for the Fiscal Year 2022